Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 5/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10516 | 0.97 | — | — | |
| SCHEMBL29287853 | 0.94 | ADRB2 (0.41) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL252597 | 0.88 | THRB (0.39) | TSHRCA1CA2THRB | |
| Ethylene Glycol SCHEMBL7173613 | 0.87 | TSHR (0.48) | ADRB2ADRB1ADRB3TSHRCYP3A4 | |
| SCHEMBL24829886 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB | |
| SCHEMBL4505591 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB | |
| SCHEMBL4493956 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB | |
| SCHEMBL278721 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB | |
| SCHEMBL2647917 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB | |
| SCHEMBL127022 | 0.86 | THRB (0.44) | TSHRCA1CA2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6624311-B2 | Forming roxifiban | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-09-23 | — | — | US | disclosed |
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | BRITOL-MYERS SQUIBB COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160465-A1 | Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester | ANPEP, DAO, DNPEP | ADRB2 1985/4885ADRB1 1822/4885ADRB3 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.